瑞舒伐他汀对冠心病患者血脂水平及颈动脉粥样硬化斑块硬化程度的影响

目的:探讨瑞舒伐他汀对冠心病患者血脂水平以及颈动脉粥样硬化斑块硬化程度的影响。方法:选择2013年2月至2014年12月我院收治的132例冠心病患者作为研究对象,将其随机分为研究组(66例)和对照组(66例),研究组应用瑞舒伐他汀(rosuvastatin calcium,RC)治疗,对照组采用常规药物治疗,观察和比较两组患者的血脂水平变化情况及颈动脉粥样硬化斑块硬化(IMT)程度的改善情况。结果:两组的总胆固醇(total c holesterol,T C)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)、甘油三酯(triglyceride,T G)水平较治疗前均有降低,高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)水平较治疗前有升高,研究组变化更显著,组间差异有统计学意义(P0.05)。两组颈动脉粥样硬化斑块硬化程度较治疗前有改善,研究组优于对照组,差异有统计学意义(P0.05)。研究组与对照组治疗总有效率分别为98.5%、71.2%,差异有统计学意义(P0.05)。结论:瑞舒伐他汀能够有效降低冠心病患者的血脂水平,并能改善其颈动脉粥样硬化的程度。

Effect of Rosuvastatin on the Plasma Lipids Levels and the Degree of Carotid Atherosclerotic Plaques of Patients with Coronary Heart Disease

Objective:To study the effect of rosuvastatin on the plasma lipids levels and the degree of carotid atherosclerotic plaques of patients with coronary heart disease.Methods:From February 2013 to December 2014, 132 cases of patients with coronary heart disease treated in our hospital were selected as the research object and randomly divided into the research group and the control group, 66 cases in each group, the research group was treated by rosuvastatin calcium (RC), while the control group was treated by conventional drug, the plasma lipids level and the changes of carotid atherosclerotic plaques sclerosis (IMT) degree were observed and compared between two groups.Results:The total cholesterol(TC), low density lipoprotein cholesterol(LDL-C)), triglycerides(TG) levels of both groups were significantly lower than those before treatment, while the high density lipoprotein cholesterol (HDL-C) level were significantly higher than those before treatment, the research group changed more significantly, (P<0.05). The carotid atherosclerotic plaques hardening degree were improved, the research group was better than that of control group (P<0.05). The total effective rates of research group and control group were 98.5% and 71.2%, respectively, which was significantly higher in the research group(P<0.05).Conclusion:Rosuvastatin could effectively reduce the plasma lipid levels in patients with coronary heart disease, and improve the degree of carotid atherosclerosis.